Oblato, Inc.
🇺🇸United States
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Phase 1
Active, not recruiting
- Conditions
- High-grade GliomaOligodendrogliomaAstrocytomaGlioblastoma Multiforme
- Interventions
- Drug: Mid-dose OKN-007, TIDDrug: High-dose OKN-007, TIDDrug: Low-dose OKN-007, BIDDrug: Low-dose OKN-007, TID
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Oblato, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05561374
- Locations
- 🇺🇸
Providence Saint John's Cancer Institute, Santa Monica, California, United States
🇺🇸Norton Healthcare, Louisville, Kentucky, United States
🇺🇸Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
- Conditions
- Diffuse Midline Glioma, H3 K27M-MutantDiffuse Intrinsic Pontine Glioma
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Oblato, Inc.
- Registration Number
- NCT05518838
- Locations
- 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸Arkansas Children's Research Institute, Little Rock, Arkansas, United States
🇺🇸Arnold Palmer Hospital for Children, Orlando, Florida, United States
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Phase 2
Active, not recruiting
- Conditions
- Brain GlioblastomaRecurrent Malignant Glioma
- Interventions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Oblato, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT04388475
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Lifespan Office of Research, Providence, Rhode Island, United States
🇺🇸The University of Toledo, Toledo, Ohio, United States
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Oblato, Inc.
- Registration Number
- NCT03649464
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Oblato, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01672463
- Locations
- 🇺🇸
Oklahoma University, Oklahoma City, Oklahoma, United States
© Copyright 2025. All Rights Reserved by MedPath